ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2015
Double- and multi-carbapenemase-producers: the excessively armored bacilli of the current decade.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 56 citations in OpenAlex.
- Emergence and dissemination of an IncC plasmid co-harbouringJAC-antimicrobial resistance · 2026Article
- Article
- Mechanisms, Significance, Detection and Emerging Therapies for Carbapenem-Resistant Enterobacterales: A Scoping Review.Journal of tropical medicine · 2026Review
- Thirty-Day Mortality Associated With Carbapenemase-ProducingOpen forum infectious diseases · 2025Article
- Reporting antimicrobial susceptibility and detection of carbapenemase production in single and double carbapenemase-producing Gram-negative clinical isolates: a nationwide proficiency study.Frontiers in microbiology · 2025Article
- Article
- Characterization of carbapenem-resistant Enterobacterales andJournal of clinical microbiology · 2024Article
- Global emergence of double and multi-carbapenemase producing organisms: epidemiology, clinical significance, and evolutionary benefits on antimicrobial resistance and virulence.Microbiology spectrum · 2024Article
- Investigating the relationship between carbapenemase production and biofilm formation in Klebsiella pneumoniae clinical isolates.BMC research notes · 2024Article
- Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem-resistantMicrobiology spectrum · 2024Article
- Clinical, microbiological and genomic characterization of Gram-negative bacteria with dual carbapenemases as identified by rapid molecular testing.JAC-antimicrobial resistance · 2024Article
- Three separate acquisitions of blaEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Dissemination and characteristics of carbapenem-resistantFrontiers in microbiology · 2023Article
- Characterization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Molecular Characterization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- High-Risk Clone ofInternational journal of environmental research and public health · 2022Article
- Genetic Characterization and Passage Instability of a Hybrid Plasmid Co-HarboringMicrobiology spectrum · 2021Article
- Genomic characterization of triple-carbapenemase-producingJAC-antimicrobial resistance · 2021Article
- Detection and Characterization of Targeted Carbapenem-Resistant Health Care-Associated Threats: Findings from the Antibiotic Resistance Laboratory Network, 2017 to 2019.Antimicrobial agents and chemotherapy · 2021Article
- The Gut Microbiome as a Reservoir for Antimicrobial Resistance.The Journal of infectious diseases · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative nosocomial pathogens commonly carry one carbapenemase gene conferring resistance to carbapenems and other beta-lactam antibiotics. However, increasing reports show that double-carbapenemase-producing (DCP) and even multi-carbapenemase-producing (MCP) bacteria are emerging in some parts of the world, diminishing further, in some cases, the already limited treatment options. In the present review, the up-to-date reports of DCP and MCP isolates are summarized and concerns regarding their emergence are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.